How do you manage PSA progression while a patient is on Xofigo or Pluvicto?

If a patient has clinical or biochemical progression while on either of these radiopharmaceuticals, would you stop the treatment or continue?

Answer from: Radiation Oncologist at Community Practice

The tl;drPSA is very much an imperfect tool for these patients. The data show that PSA may initially increase over multiple cycles before decreasing, though this is a minority of patients. Most patients whose PSA increases early have resistant disease, and you should investigate further with imaging...

Comments

Medical Oncologist at Los Angeles VA Medical Center
Hi, Dr. @Andrew B. Thompson, thank you for your re...

Radiation Oncologist at Corewell Health
It's a really good question, Dr. @Anthony Bejjani,...

Answer from: Medical Oncologist at Community Practice

Change of therapy depends on evaluation after sufficient time has elapsed from the start, and on a fuller picture with ancillary studies.

Please select the option that best describes you:

How do you manage PSA progression while a patient is on Xofigo or Pluvicto?

Related Questions